Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384797 · ClinicalTrials.gov registry record
Blood Biomarker in Early Parkinson's Disease
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 65
- Enrollment target
NCT03384797: Completed study, sponsored by Duke University.
NCT03384797 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03384797 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.
Primary Outcome
Test for biological marker of Parkinson's disease, mtDNA damage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-07 |
What the finished NCT03384797 record still lists
NCT03384797 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03384797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03384797 about?
NCT03384797 is a clinical study titled "Blood Biomarker in Early Parkinson's Disease". Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to meas...
What is the current status of trial NCT03384797?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2018-01-22. Estimated completion is 2019-01-07.
Who is sponsoring clinical trial NCT03384797?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI